title: Control Process for Manufacturing and Standardization of Allergenic Molecules.
abstract: It is widely accepted that the success of the allergen immunotherapy (AIT), beyond clinical parameters such as dose, dosage regimen, or compliance, depends on the quality and composition of the final products used in the vaccines. Allergenic vaccines are pharmaceutical preparations derived from the natural sources which contain the allergenic components responsible for allergic sensitization. The selection of the appropriate allergenic sources must be a requirement. They suffer a dramatic transformation during the manufacturing process which renders a biologically standardized final product. The inclusion of the appropriate control analyses in the manufacturing process has demonstrated to be an efficient method to guarantee the quality and homogeneity of the final product as well as being a very useful tool for saving time and money. In this context, in the last years, the Regulatory Agencies have released specific guidelines to guarantee the manufacturing of the most appropriate products for the treatment of patients.
authors.affiliation: R&D Department, Laboratorios LETI SLu, C/ Sol n° 5, Tres Cantos, Madrid, Spain, jcarnes@leti.com.
authors.forename: Jerónimo
authors.initials: J
authors.lastname: Carnés
authors.forename: Víctor
authors.initials: V
authors.lastname: Iraola
authors.forename: Mayte
authors.initials: M
authors.lastname: Gallego
authors.forename: Jose R
authors.initials: JR
authors.lastname: Leonor
mesh_terms: D000485:Allergens / Q000276:immunology; D000818:Animals; D003888:Desensitization, Immunologic / Q000379:methods; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology*; D017410:Practice Guidelines as Topic; D014612:Vaccines / Q000276:immunology
chemical_list: D000485:Allergens; D014612:Vaccines